Risk of mortality in patients with cancer who experience febrile neutropenia.
about
Biosimilars in the management of neutropenia: focus on filgrastimRisk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis.The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma.Therapeutic strategies for chemotherapy-induced neutropenia in patients with solid tumors.Quantitative impact of neutrophils on bacterial clearance in a murine pneumonia modelEpidemiology and characteristics of febrile neutropenia in oncology patients from Spanish tertiary care hospitals: PINNACLE study.Preventing infections during cancer treatment: development of an interactive patient education websiteThe glutathione disulfide mimetic NOV-002 inhibits cyclophosphamide-induced hematopoietic and immune suppression by reducing oxidative stress.Guideline-Based Peer-to-Peer Consultation Optimizes Pegfilgrastim Use With No Adverse Clinical Consequences.Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?Trends in neutropenia-related inpatient events.Immune Modulation From Five Major Mushrooms: Application to Integrative Oncology.Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice.Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy.Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.Developing a tool for nurses to assess risk of infection in pediatric oncology patients in China: a modified Delphi study.Pharmacoeconomics of the myeloid growth factors: a critical and systematic review.Management of febrile neutropenia in pediatric oncology across Queensland, Australia: a retrospective review on variations between locations.Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia.Is parenteral chemotherapy safe in rural hospitals? A prospective audit of neutropenic fever in Albany Hospital, a regional West Australian cancer centre.Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement.Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.Travel burden associated with granulocyte colony-stimulating factor administration in a Medicare aged population: a geospatial analysis.Use of prophylactic growth factors and antimicrobials in elderly patients with cancer: a review of the Medicare database.Cost of Cancer-Related Neutropenia or Fever Hospitalizations, United States, 2012.The association of hyperglycemia and diabetes mellitus and the risk of chemotherapy-induced neutropenia among cancer patients: A systematic review with meta-analysis.Reducing excessive toxicity in ovarian cancer treatment: a personalized approach.Predictors of Outcome and Severity in Adult Filipino Patients with Febrile Neutropenia.Infection-related mortality in Hispanic and non-Hispanic children with cancer.Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings.Chronic comorbid conditions associated with risk of febrile neutropenia in breast cancer patients treated with chemotherapy.Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cCosts associated with febrile neutropenia in the US.Risk of infection among patients with non-metastatic solid tumors or non-Hodgkin's lymphoma receiving myelosuppressive chemotherapy and antimicrobial prophylaxis in US clinical practice.Efficacy of reduced dose of pegfilgrastim in Japanese breast cancer patients receiving dose-dense doxorubicin and cyclophosphamide therapy.Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy--a representative sample survey in Germany.Comorbidities among patients with cancer who do and do not develop febrile neutropenia during the first chemotherapy cycle.Mortality, length of stay, and health care costs of febrile neutropenia-related hospitalizations among patients with breast cancer in the United States.The use of an early alert system to improve compliance with sepsis bundles and to assess impact on mortality.
P2860
Q26764906-41B61FD0-78D0-4AB3-A84A-563AB09D97C9Q33602351-7858C7D9-CDC5-45FE-9ADA-CBB848618820Q33752272-BA0719A5-E18C-460D-9209-9A8C7F8F3FC3Q34670717-A6D7B71D-FAFF-45AA-A5B2-8DCD32292594Q35270290-82A6A7E1-6DAB-4A08-B0A0-29A47E230404Q35753638-FADD8CE0-255C-42B8-9B9C-89732F74CDEEQ35760041-C5FFB325-9884-4DEF-BACB-8E087F3539A8Q35925964-32C902F1-B287-4244-8B3E-63CB59547E18Q35947740-9CE0DA16-4FF4-45ED-B92E-33B13842AAF0Q36023851-DF055A19-FDB6-48E4-8ACE-B9319B553C0FQ36095153-CFACEA5C-78E8-42D6-86EC-E5C5BB992EECQ36384392-8E5C2950-42AB-4242-8F9D-8E0FBE6582C2Q36723903-5CF8B7EC-912C-4807-BB72-E29916E815ECQ36840636-6EB7DD23-0F31-41DB-B50D-13771DD1F8B8Q36885665-56C8354B-1742-4A0F-8DCD-37C1E4B9F6D0Q37045421-226481AF-C151-4524-B157-662EB8935257Q37300122-BAAD6931-7FDF-44C2-AEC9-578B20638C1BQ38006021-A5665F29-1E36-4C43-9246-511FD62D3798Q38174794-D0BAFA9C-CCB6-4155-A333-6B94D2F46818Q38269589-F4B93400-1AD5-4894-9ADE-3C4DF4B698E1Q38559000-E014828C-3054-47C4-B933-0C57987B090DQ38608267-D01F7BA7-0FF3-4B5A-8C8C-238F65D0EEFEQ38613025-D8B8B58D-AD46-4DBF-812D-FC1497CAFAB8Q38672480-90B62866-7D39-4B0A-8DE1-76F2F9DE8EC1Q38812563-285CEE5C-9497-4951-8740-A3C6C9CF4ACCQ38823135-8137EF7B-8184-42CC-86FC-580A1D73A853Q38983276-E25A060A-D434-4858-B4BB-AFF79B4F7CF5Q39739012-A0690207-185A-47A2-8FAE-B4D61F7F18AAQ40137108-6ECF8CD3-0C22-483A-8FBC-B45660D1FE0FQ40240367-0989F3E0-253C-41D5-B4C5-7D31D8217950Q40242261-B9CC51E8-DD7B-4D7E-A3A1-9C0A658047B0Q40255259-0729C1EA-E28A-420B-B284-115B066FE15BQ40274712-0B720DC6-2EDE-4A6C-A3F1-E08F61B3216CQ40280346-D032407C-A8CA-4778-B582-8F3C4FF547B5Q40320980-2BBA0A61-EAAE-4FC8-A843-680F2246F7F1Q40364449-4E90C4D3-B5DD-4C31-8F87-7373ADEF5EF4Q40829486-30AE1D3B-F9F7-4408-A624-1D8EB859B80EQ41349270-4F562E08-B641-4C4D-A531-050740D7C729Q41628706-8C289491-391F-4716-B865-21200A916363Q42593732-7BBF35A8-65F4-4D60-AD13-AAC634EBEC8D
P2860
Risk of mortality in patients with cancer who experience febrile neutropenia.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Risk of mortality in patients with cancer who experience febrile neutropenia.
@en
type
label
Risk of mortality in patients with cancer who experience febrile neutropenia.
@en
prefLabel
Risk of mortality in patients with cancer who experience febrile neutropenia.
@en
P2093
P2860
P356
P1433
P1476
Risk of mortality in patients with cancer who experience febrile neutropenia.
@en
P2093
Gary H Lyman
Karen Smoyer Tomic
Matthew W Reynolds
Rich Barron
Shannon L Michels
P2860
P304
P356
10.1002/CNCR.25332
P407
P577
2010-08-16T00:00:00Z